H3B-5942
CAS No. 2052128-15-9
H3B-5942 ( H3B5942 )
产品货号. M13184 CAS No. 2052128-15-9
H3B-5942 is an orally available, selective estrogen receptor covalent antagonist (SERCA), demonstrates potent ERαantagonist activity in vitro and in vivo.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1531 | 有现货 |
|
10MG | ¥2373 | 有现货 |
|
25MG | ¥4601 | 有现货 |
|
50MG | ¥6577 | 有现货 |
|
100MG | ¥8748 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称H3B-5942
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述H3B-5942 is an orally available, selective estrogen receptor covalent antagonist (SERCA), demonstrates potent ERαantagonist activity in vitro and in vivo.
-
产品描述H3B-5942 is an orally available, selective estrogen receptor covalent antagonist (SERCA), demonstrates potent ERαantagonist activity in vitro and in vivo; covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation; demonstrated significant single-agent antitumor activity in xenograft models representing ERαWT and ERα Y537S breast cancer that was superior to fulvestrant.
-
同义词H3B5942
-
通路Endocrinology/Hormones
-
靶点Estrogen Receptor/ERR
-
受体Estrogen Receptor/ERR
-
研究领域——
-
适应症——
化学信息
-
CAS Number2052128-15-9
-
分子量494.64
-
分子式C31H34N4O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCCC(=C(C1=CC=C(C=C1)OCCNCC=CC(=O)N(C)C)C2=CC3=C(C=C2)NN=C3)C4=CC=CC=C4
-
化学全称(E)-4-((2-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)amino)-N,N-dimethylbut-2-enamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Puyang X, et al. Cancer Discov. 2018 Jul 10. pii: CD-17-1229.
产品手册
关联产品
-
Allylestrenol
Allylestrenol is a synthetic steroid with progestational activity.
-
17-Beta-Estradiol-3,...
Estradiol dipropionate is a synthetic ester, specifically the 3,17-dipropanoyl ester, of the natural estrogen, estradiol.
-
Enclomiphene citrate
Enclomiphene citrate((E)-Clomifene, cis-Clomifene, RMI-16289, ICI-46476)is a nonsteroidal selective estrogen receptor modulator (SERM) that is under development for the treatment of male hypogonadism.